A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older

被引:0
作者
Manuela Tamburro
Giancarlo Ripabelli
Antonio D’Amico
Roberta De Dona
Mariagrazia Iafigliola
Albino Parente
Nicandro Samprati
Arturo Santagata
Carmen Adesso
Anna Natale
Michela Anna Di Palma
Fabio Cannizzaro
Michela Lucia Sammarco
机构
[1] University of Molise,Department of Medicine and Health Sciences “Vincenzo Tiberio”
[2] University of Molise,School of Specialization in Hygiene and Preventive Medicine
来源
Journal of Community Health | 2022年 / 47卷
关键词
Active surveillance; Adverse reactions; COVID-19 booster vaccination; Comirnaty; Spikevax; Safety;
D O I
暂无
中图分类号
学科分类号
摘要
A booster dose after primary COVID-19 vaccination series was considered crucial after the emergence of the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants. Active surveillance was used to investigate reporting of adverse events post-booster dose of either of the licensed mRNA Comirnaty (Pfizer/BioNTech) or Spikevax (Moderna) vaccines in adult (17 years and older) recipients in central Italy. Eligible participants were enrolled and interviewed via phone using a structured questionnaire. Primary outcomes related to the occurrence of adverse events post-booster were stratified by vaccine, and frequency of local/systemic, mild/moderate/severe events. Of a total of 622 participants interviewed, 554 (89.1%) reported at least one adverse event (88.2% and 92.9% after the Comirnaty or Spikevax vaccine, respectively): 63.4% were female, and 78.5% aged 17 to 64 years, regardless of vaccine. 87.7% and 68.2% of all recipients described at least one local or systemic reaction, respectively: 97.3, 38.6 and 4.7% reported mild, moderate, or severe events, respectively. The most frequent adverse reactions were pain, redness, or swelling at the injection site and fatigue, while malaise and fever significantly occurred after the Comirnaty, and vomiting after the Spikevax booster. Compared to the primary vaccination, lymphadenopathy was more common after the booster (p < 0.001), especially after Comirnaty vaccine. The study findings revealed no serious or unexpected adverse events, and are in agreement with data available on booster dose for both mRNA vaccines. The transient, mild to moderate, and common to very common side reactions reported should be used to reassure potential recipients of the lack of safety concerns.
引用
收藏
页码:814 / 821
页数:7
相关论文
共 170 条
[51]  
Li M(undefined)undefined undefined undefined undefined-undefined
[52]  
Cui Y(undefined)undefined undefined undefined undefined-undefined
[53]  
Chen Y(undefined)undefined undefined undefined undefined-undefined
[54]  
Yang L(undefined)undefined undefined undefined undefined-undefined
[55]  
Liu J(undefined)undefined undefined undefined undefined-undefined
[56]  
Zhu H(undefined)undefined undefined undefined undefined-undefined
[57]  
Jiang S(undefined)undefined undefined undefined undefined-undefined
[58]  
Wang P(undefined)undefined undefined undefined undefined-undefined
[59]  
Pierobon A(undefined)undefined undefined undefined undefined-undefined
[60]  
Dal Zotto A(undefined)undefined undefined undefined undefined-undefined